The University of Virginia has announced a new partnership with AstraZeneca, one of the world’s largest and leading pharmaceutical companies.
According to a press release, the multi-year collaboration is geared toward the development of new treatments for coronary artery disease and peripheral vascular disease.
Although the financial terms were not released, for Thomas Skalak, UVA’s vice president for research, the partnership is a step in the right direction in terms of translational research, which President John Casteen deemed vital at a dinner last month.
